logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
M

María Vieito

vall d'hebron university hospital

25H-index
314Paper Count
2.2KCitation Count
Published Papers 93
Publication Date
logo
Progression-Free Survival 2 as a Potential Surrogate for Overall Survival in Glioblastoma: Insights From a Spanish Multicentric Cohort
errCancer Medicine
IF3.1
err2026-04-19
err0
errOAAI
errJesús Yaringaño; Oriol Mirallas; Víctor Navarro; Diego Gómez-Puerto; Gabriel Velilla; María Ángeles Vaz; Teresa Gorria; Álvaro Martínez-Monino; Ainhoa Hernández; María Aguado; Antonio Di Muzio; Daniel López Valbuena; Fiorella Ruiz-Pace; Macarena González; María Martínez-García; Guillermo Villacampa; Carmen Balaña; Joan Carles; Rodrigo Dienstmann; Estela Pineda; Juan Manuel Sepúlveda; María Vieito
errShare
errSave
Evolving landscape of targeted therapies in early phase clinical trials
errEuropean Journal of Cancer
IF7.1
err2026-04-12
err0
PREAI
errAlice Rossi; Irene Braña; Maria Vieito; Oriol Mirallas; Victor Navarro; Omar Saavedra; Guzman Alonso Casal; Vladimir Galvao; M Julia Lostes Bardaji; Arjun Oberoi; Giulia Pretelli; Marta Sanz; Sergio Andres Bueno; Benet Fite Abril; Susana Aguilar Izquierdo; Jose Jimenez; Paolo Nuciforo; Ana Vivancos; Mafalda Oliveira; Iosune Baraibar
errShare
errSave
Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey
errClinical and Translational Oncology
IF2.5
err2026-01-10
err0
errOAAI
errJavier-David Benítez-Fuentes; Regina Gironés Sarrió; Victoria García Samblás; Mónica Guillot Morales; Patricia Palacios Ozores; Ana Ruiz-Casado; Javier Torres-Jiménez; María Vieito Villar
errShare
errSave
Climate disasters and cancer care: the Valencia DANA as a case for system resilience
errClinical and Translational Oncology
IF2.5
err2026-01-03
err0
PREAI
errJavier-David Benitez-Fuentes; Victoria García Samblás; Mónica Guillot Morales; Patricia Palacios Ozores; Ana Ruiz Casado; Javier Torres Jiménez; María Vieito Villar; Regina Gironés Sarrió
errShare
errSave
Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions
errClinical and Translational Oncology
IF2.5
err2025-12-10
err0
errOAAI
errRegina Gironés Sarrió; Javier David Benítez Fuentes; Victoria García Samblás; Mónica Guillot Morales; Patricia Palacios Ozores; Ana Ruiz-Casado; Javier Torres-Jiménez; María Vieito Villar
errShare
errSave
Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI
errCommunications Medicine
IF6.3
err2025-11-20
err0
errOAAI
errFrancesco Grussu; Athanasios Grigoriou; Kinga Bernatowicz; Marco Palombo; Irene Casanova-Salas; Daniel Navarro-Garcia; Ignasi Barba; Sara Simonetti; Garazi Serna; Carlos Macarro; Anna Kira Voronova; Valezka Garay; Juan Francisco Corral; Marta Vidorreta; Pablo García-Polo García; Xavier Merino; Richard Mast; Núria Rosón; Manuel Escobar; Maria Vieito; Rodrigo Toledo; Paolo Nuciforo; Joaquin Mateo; Elena Garralda; Raquel Perez-Lopez
errShare
errSave
A PHASE 1 STUDY OF TINOSTAMUSTINE, A NOVEL ALKYLATING DEACETYLASE INHIBITOR, AS ADJUVANT TREATMENT IN NEWLY DIAGNOSED MGMT PROMOTER-UNMETHYLATED (UMGMT) GLIOBLASTOMA (GBM)
errNEURO-ONCOLOGY
IF13.4
err2025-11-01
err0
errOAAI
errRoth, Patrick; Candilejo, Irene Moreno; Salgado, Maria Angeles Vaz; Hundsberger, Thomas; Tomas, Janik; Vieito, Maria
errShare
errSave
Pemigatinib for previously treated metastatic or unresectable central nervous system tumors with fibroblast growth factor receptor mutations or rearrangements: FIGHT-207 results
errONCOLOGIST
IF4.2
err2025-11-01
err0
errOAAI
errSpanggaard, Iben; Matrana, Marc; Rocha Lima, Caio; Mahipal, Amit; Vieito, Maria; Hervieu, Alice; Goyal, Lipika; Rodon, Jordi; Veronese, Maria Luisa; Oliveira, Natalia; Li, Xin; Schaffer, Michael; Kesari, Santosh
errShare
errSave
EO2401 PEPTIDE IMMUNOTHERAPY plus NIVOLUMAB plus /- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)
errNEURO-ONCOLOGY
IF13.4
err2025-11-01
err0
errOAAI
errReardon, David A.; Idbaih, Ahmed; Vieito, Maria; Ghiringhelli, Francois; Stradella, Agostina; Tabatabai, Ghazaleh; Burger, Michael C.; Mildenberger, Iris; Herrlinger, Ulrich; Wen, Patrick Y.; Touat, Mehdi; Wick, Antje; Gonzalez, Macarena; Hervieu, Alice; Gil-Martin, Marta; Renovanz, Mirjam; Gouttefangeas, Cecile; Maia, Ana; Chene, Laurent; Fagerberg, Jan; Rinaudo, Philippe; Wick, Wolfgang
errShare
errSave
A PHASE 1 STUDY OF TINOSTAMUSTINE, A NOVEL ALKYLATING DEACETYLASE INHIBITOR, AS ADJUVANT TREATMENT IN NEWLY DIAGNOSED MGMT PROMOTER-UNMETHYLATED GLIOBLASTOMA
errNEURO-ONCOLOGY
IF13.4
err2025-10-01
err0
errOAAI
errRoth, P.; Candilejo, I. Moreno; Salgado, M. A. Vaz; Hundsberger, T.; Janik, T.; Vieito, M.
errShare
errSave
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
errNature Medicine
IF50
err2025-07-30
err0
errOAAI
errScott Kopetz; Valentina Boni; Ken Kato; Kanwal P. S. Raghav; Maria Vieito; Athanasios Pallis; Christina Habermehl; Abdul Siddiqui; Perrine Courlet; Willem Sloot; Sabine Raab-Westphal; Felix Hart; Ildefonso Rodriguez-Rivera
errShare
errSave
A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
errESMO OPEN
IF8.3
err2025-03-01
err0
PREAI
errSchram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
errShare
errSave
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma
errNEURO-ONCOLOGY ADVANCES
IF4.1
err2025-01-01
err1
errOAAI
errWhittle, James R.; Vieito, Maria; Rohrberg, Kristoffer; Rodriguez-Ruiz, Maria E.; Castanon, Eduardo; Mellinghoff, Ingo K.; Van Linde, Myra; Cloughesy, Timothy; Reardon, David A.; Chong, Robert A.; Rosenthal, Mark; Wick, Antje; Waldhauer, Inja; Henkel, Nina; Romagnoli, Barbara; Wolowski, Vincent; Dey, Shuva; Heil, Florian; Heichinger, Christian; Flinn, Nick; Gou, Jean-Philippe; Smith, Lance; Prince, Frederic; Derks, Michael; Roller, Andreas; Schiff, Christina; Schneider, Meike; Mason, Warren
errShare
errSave
A PRELIMINARY SIGNS OF CLINICAL ACTIVITY OF TUVUSERTIB (M1774), A HIGHLY POTENT ORAL ATR INHIBITOR, IN REFRACTORY IDH MUTATED GLIOMA PATIENTS WITH P53 AND ATRX MUTATIONS; A CASE SERIES FROM A FIH STUDY
errNEURO-ONCOLOGY
IF13.4
err2024-10-17
err0
PREAI
errVieito, M.; Moreno, I; Gomez-Puerto, D.; Ruiz, I. Victoria; Indacochea, A.; Garralda, E.; Gonzalez, S.; Calvo, E.; Juanita, L.; Szucs, Z.; Reischmann, N.; Pineda, E.
errShare
errSave
MENINGIOMA: A CHALLENGE FOR RADIOLIGAND THERAPY. THE INITIAL EXPERIENCE OF TWO EUROPEAN CENTRES
errNEURO-ONCOLOGY
IF13.4
err2024-10-17
err0
PREAI
errAsadurova, S.; Flaus, A.; Garcia-Burillo, A.; Lorenzo-Bosquet, C.; Lachachi, B.; Al Mansour, L.; Gonzalez, M.; Vieito, M.; Gamez-Cenzano, C.
errShare
errSave
Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations
errEUROPEAN JOURNAL OF CANCER
IF7.1
err2024-10-01
err0
PREAI
errPiha-Paul, S.; Garralda, E.; Vieito, M.; Oh, D. Y.; Huang, J.; Villalona-Calero, M.
errShare
errSave
EphA2-targeting bicycle toxin conjugate (BTC) BT5528 in patients (pts) with advanced solid tumors: A phase I/II study
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errFontana, E.; Wang, J. S.; Mckean, M.; Aljumaily, R.; Machiels, J-P.; Doger de Speville, B.; Vieito, M.; Carter, L.; Prenen, H.; Falchook, G. S.; Greystoke, A.; Feliu, W. I. Ortuzar; De, A.; Gu, X.; Li, M.; de Rienzo, A.; Bashir, B.
errShare
errSave
Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err2
PREAI
errVieito, M.; Mckean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Moreno Garcia, V.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; Korakis, I.; Van Tine, B. A.; Ma, V. T-L.; Ali, A.; Hinojosa, E.; Lobbardi, R.; Liu, H.; Hurh, E.; Reyno, L.; Buchbinder, E.
errShare
errSave
The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errVega Cano, K.; Garre, J.; Nunez, F.; Gomez, M.; Mascaro Baselga, P.; Yaringano Cerna, J.; Mirallas, O.; Gomez Puerto, D.; Molina Lores, G.; Auger, C.; Lopez, C.; Herbera, S.; Martinez, F.; Marmolejo Castaneda, D.; Gonzalez Rodriguez, M.; Maldonado, X.; Vieito, M.
errShare
errSave
Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
errANNALS OF ONCOLOGY
IF65.4
err2024-09-01
err0
PREAI
errLostes Bardaji, M. J.; Mel Olano, A.; Mirallas, O.; Morchon Araujo, D.; Perez Fernandez, S.; Raskina, K.; Galvao, V.; Alonso Casal, G.; Oberoi, A.; Pretelli, G.; Rojas Laimito, K. I.; Ortega Morillo, B.; Ortiz Velez, C.; Munoz-Couselo, E.; Viaplana, C.; Vieito, M.; Brana, I.; Dienstmann, R.; Hernando Calvo, A.; Garralda, E.
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
D
Dirk Schadendorf
H-index: 182 · Papers: 2.4K
F
F. Stephen Hodi
H-index: 156 · Papers: 1.5K
J
Josep Tabernero
H-index: 146 · Papers: 2.7K
P
Patrick Y. Wen
H-index: 145 · Papers: 1.9K
W
Wolfgang Wick
H-index: 142 · Papers: 1.6K
View more